Periinterventional Coagulation Management of Patients Undergoing a TIPS
Optimizing Periinterventional Coagulation Management of Patients Undergoing a Transjugular Intrahepatic Portosystemic Shunt Implantation: A Prospective Randomized Cohort Study
Medical University of Graz
39 participants
May 27, 2020
INTERVENTIONAL
Conditions
Summary
Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective
Eligibility
Inclusion Criteria3
- Liver cirrhosis
- \>18 years
- Indication for TIPS implantation
Exclusion Criteria9
- Contraindications against TIPS implantation
- Hepatocellular carcinoma BCLC D
- Ongoing bleeding
- pre-existing anticoagulant therapy at time of inclusion
- administration of blood products within 1 week prior to the enrolment
- Other malignancies that lead to an impaired 90-day survival
- Inherit blood clotting disorders
- Hepatic encephalopathy grade 3 or 4
- any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol
Interventions
Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
2\) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04421924